# CD70-targeted immunoPET Imaging of Malignant Cancers

> **NCT06852638** · PHASE2 · RECRUITING · sponsor: **RenJi Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Renal Cancer
- Renal Clear Cell Carcinoma
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** [18F]F-RESCA-RCCB6
- **DRUG:** [18F]F-RESCA-R8B4
- **DRUG:** [68Ga]Ga-NOTA-R8B4
- **DRUG:** [18F]F-RESCA-RD06
- **DRUG:** [68Ga]Ga-NOTA-RD06

## Key facts

- **NCT ID:** NCT06852638
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-23
- **Primary completion:** 2026-12-23
- **Final completion:** 2026-12-23
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06852638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06852638, "CD70-targeted immunoPET Imaging of Malignant Cancers". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT06852638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*